Picture India in the 1930s. The country cannot manufacture its own medicines. Every tablet, every vial, every dose of quinine comes from abroad, priced however foreign companies see fit, available only when foreign companies decide to ship it. If you’re poor and sick, you may simply not be able to afford to get better. That was the reality Dr. Khwaja Abdul Hamied set out to change  and the company he built to change it, Cipla, is now one of the reasons India is called the “pharmacy of the world.”

This is not just a business story. It’s the story of a chemist who treated a colonial injustice as a scientific problem to solve, who kept a promise made to Mahatma Gandhi for the rest of his life, and whose son later stared down the world’s biggest pharmaceutical companies to make a single AIDS drug cost a dollar a day instead of thousands.

Ninety years on, Cipla’s journey remains one of the clearest examples of what happens when a founder’s personal conviction becomes a company’s permanent DNA.

Table of Contents

1. The Spark: A Young Man Radicalised by Empire
2. Berlin, a PhD, and a Promise to Gandhi
3. 1935: Founding Cipla on Rs. 2 Lakhs and a Principle
4. The War Years: Quinine, Necessity, and National Pride
5. The Gandhi Visit That Sealed the Mission
6. Passing the Torch: Yusuf Hamied Joins the Family Business
7. Breaking Patent Law, Breaking Prices
8. The $1-a-Day AIDS Drug That Shook the World

  9. Cipla Today: The Legacy in Numbers

 10. What the Cipla Story Teaches About Building for Impact

 11. Final Thoughts

 12. Frequently Asked Questions

The Spark: A Young Man Radicalised by Empire

Khwaja Abdul Hamied was born on 31 October 1898 in Aligarh, in what was then British India. He wasn’t born into activism — he arrived at it. As a teenager, he witnessed an act of colonial highhandedness that lit a fire of nationalism in him at the age of fifteen, and that fire, by every account, never really went out.

He studied at Muir Central College and the University of Allahabad, and it was there that chemistry caught hold of him — not as an abstract academic pursuit, but as a tool. If India was going to be truly independent, he reasoned, it couldn’t remain dependent on foreign powers for the basics of survival. Medicine was one of those basics.

Pro Insight: Hamied’s activism and his science were never separate tracks. Nearly every major decision in his career — where he studied, what he researched, what he built  traces back to the same question: how do I make India self-sufficient?

Berlin, a PhD, and a Promise to Gandhi

In 1924, inspired by the Swadeshi movement and Gandhi’s call for Indian self-reliance, Hamied set sail for Europe to pursue a doctorate in chemistry. He enrolled at Friedrich Wilhelm University in Berlin (now Humboldt University), researching the technology of barium compounds, and earned his PhD three years later.

A few things made this choice unusual for its time:

• A scientific answer to a political problem. Most nationalists of the era fought colonialism with speeches and protest. Hamied chose a doctorate.
• A long voyage, a longer plan. Sailing back to India in October 1927, he reportedly spent the journey mapping out his future, refusing to waste the trip on idle time.
• No safety net. He returned to an India with no real domestic pharmaceutical industry, choosing to build one from nothing rather than join an established foreign firm.

He came home with more than a degree. He came home with a mission.

1935: Founding Cipla on Rs. 2 Lakhs and a Principle

It took Hamied nearly a decade after returning to India to gather the resources and the right people. In 1935, he brought together a group of friends and founded The Chemical, Industrial and Pharmaceutical Laboratories — the company that would eventually shorten its name to Cipla.

What made it different from the start wasn’t scale, it was intent. The company launched with just Rs. 2 lakhs in capital — a modest sum even by 1930s standards — and a goal that had nothing to do with luxury or export glory: making healthcare accessible to ordinary Indians who otherwise had none. The founding vision leaned specifically on local ingredients and local manufacturing rather than imports, and by 1937, two years after founding, Cipla began production, making it the oldest pharmaceutical company in India.

None of this happened in a friendly environment. India had almost no pharmaceutical manufacturing base at the time, limited access to capital, and a colonial government with no particular interest in helping an Indian-owned drug company succeed. Hamied built anyway.

The War Years: Quinine, Necessity, and National Pride

World War II turned out to be an unlikely proving ground for Cipla. With international supply chains disrupted, the company stepped into a role nobody could have planned for.

During the war, Cipla became the largest supplier of quinine and Vitamin B12 for Allied soldiers — a striking turn for a company founded explicitly to reduce India’s dependence on foreign powers, now supplying medicine that those same powers desperately needed. It was proof, delivered under wartime pressure, that Indian manufacturing could meet a global standard when it had to.

The Gandhi Visit That Sealed the Mission

In 1939, Mahatma Gandhi visited Cipla’s offices — a moment the company still refers to as one of the defining points in its history. The visit didn’t just validate the company publicly. It personally strengthened Hamied’s resolve, and he is said to have made a private commitment that day: “never again will India be starved of essential drugs.”

Pro Insight: That single sentence became something close to a mission statement Cipla has repeated for generations. Long before “purpose-driven company” was a business school phrase, Hamied had already built one.

Passing the Torch: Yusuf Hamied Joins the Family Business

Being the founder’s son didn’t come with shortcuts. Yusuf Hamied, who earned a chemistry degree from Christ’s College, Cambridge, in 1957, followed by a PhD from Cambridge, returned to India in the early 1960s expecting to contribute meaningfully. Instead, he started at the very bottom.

Here’s what the handover actually looked like:

• No fast-track. It reportedly took two years for Yusuf to even secure formal employment at Cipla, precisely because he was related to a director and the board held a strict line against nepotism.
• Ground-floor work, literally. By his own account, he spent time cleaning floors in the tablet department before ever touching research.
• Research role by 1960. He eventually joined as an officer in charge of research and development, and in 1961 the company’s Vikhroli factory began manufacturing diosgenin, opening the door to a new line of steroid and hormone products.
• The founder’s passing. Dr. K.A. Hamied died on 23 June 1972, leaving Cipla to the next generation at a pivotal moment in India’s pharmaceutical history.

Breaking Patent Law, Breaking Prices

The single most consequential thing Yusuf Hamied did for Cipla — and arguably for global public health — happened in the world of policy, not the lab.

For context: India’s patent framework going into the 1960s was still based on colonial-era law, which allowed foreign companies to hold product patents on medicines and price them accordingly, largely out of reach for most Indians. A 1959 government-commissioned report by Justice N. Rajagopala Ayyangar had already recommended moving India toward a process-patent system — one that would let domestic companies manufacture a patented drug legally, as long as they used a different production method to make it. Yusuf Hamied became one of the most vocal advocates for adopting those recommendations, reportedly pressing the case directly with Prime Minister Indira Gandhi’s government, in one instance framing the issue starkly: should millions of Indians be denied a lifesaving drug because the patent holder objected to who was using it?

That advocacy fed into a broader legislative push — Parliament had already introduced the relevant bill in 1965 and amended it in 1967 — and Hamied’s lobbying is widely credited as one of the influences behind the resulting law. India’s Patents Act was passed in 1970 and came into force in 1972, formally establishing the process-patent system the Ayyangar report had proposed. It was a technical-sounding change with enormous consequences: it legally opened the door for Indian companies to produce low-cost generic versions of drugs that multinational firms sold at far higher prices elsewhere in the world.

This single policy shift transformed India’s pharmaceutical industry and gave companies like Cipla room to grow into global generic drug manufacturers rather than remaining permanently dependent on foreign patent holders.

The $1-a-Day AIDS Drug That Shook the World

If the patent law change was the mechanism, the moment that made the world sit up was Cipla’s stand during the global AIDS crisis in the early 2000s.

At the time, AIDS medication in wealthier countries could cost around $24,000 per patient per year — a price entirely out of reach for most people in the developing world, where the disease was devastating entire communities, especially across sub-Saharan Africa. Governments and aid organizations were watching millions of preventable deaths pile up, largely because the only legally available treatment was priced for markets that could never be theirs. Yusuf Hamied made the decision to offer Cipla’s generic version to Africa at roughly $96 per patient per year, later described in interviews as close to a dollar a day.

That price wasn’t arrived at casually — it reflected the manufacturing cost advantage Cipla had spent decades building under India’s process-patent regime, the same regime Hamied himself had helped bring into existence thirty years earlier. In that sense, the AIDS drug moment wasn’t a break from the company’s history; it was the payoff of a strategy set in motion long before anyone had heard of the disease.

Why this moment mattered:

• It saved lives at scale. Millions of people in developing countries gained access to treatment that was previously financially impossible for them.
• It challenged the global pharmaceutical order. Cipla directly defied the pricing model of major Western multinational pharmaceutical companies, and did so publicly enough that it forced a wider industry conversation about access pricing.
• It made Yusuf Hamied a global figure. The move earned him international recognition well beyond the pharmaceutical industry, tying the Hamied family name permanently to the idea of medicine as a right, not just a product.

Cipla Today: The Legacy in Numbers

Nearly a century after Dr. K.A. Hamied’s first plans took shape on a ship back to India, the numbers behind Cipla tell their own story.

What the Cipla Story Teaches About Building for Impact

A founder’s principle can outlive the founder. Hamied’s 1939 promise to Gandhi is still cited by Cipla today, decades after both men are gone.

Constraints can become the mission. Colonial dependence on foreign medicine wasn’t just an inconvenience for Hamied — it became the entire reason the company exists.

Access is a strategy, not just an ethic. Pricing AIDS drugs at $96 a year wasn’t only about doing good — it built Cipla’s reputation as a global generics leader.

Succession worked because it wasn’t handed over. Yusuf Hamied’s two years of unglamorous groundwork before earning a real role helped preserve the seriousness of the company culture his father built.

Final Thoughts

It is easy looking at Cipla’s scale today, to forget that it started with Rs. 2 lakhs, a handful of friends, and one man’s refusal to accept that Indians should be at the mercy of foreign drug prices. The image of Hamied on the ship home from Berlin in 1927 is particularly revealing planning a company that did not yet exist. He was thinking years ahead, at a time when India’s pharmaceutical industry barely existed.

Dr. K.A. Hamied never lived to see his son negotiate a dollar-a-day AIDS drug for Africa. But the line between the two moments is a straight one, and it’s worth sitting with for a second: a promise made quietly to Gandhi in 1939, kept, then handed down and kept again by a son who started out mopping floors. That’s rarer than most company histories let on. It hasn’t broken yet.

Frequently Asked Questions

Who founded Cipla, and when?

Dr. Khwaja Abdul Hamied founded Cipla in 1935 in Mumbai, initially named The Chemical, Industrial and Pharmaceutical Laboratories.

Why is Cipla significant in Indian history?

Cipla was founded specifically to reduce India’s dependence on foreign pharmaceutical companies and to make essential medicines accessible to ordinary Indians, tying it closely to the broader Swadeshi and independence movements.

What role did Yusuf Hamied play?

Dr. K.A. Hamied’s son, Yusuf Hamied, led Cipla for over five decades after his father’s death. He’s best known for advocating the process-patent reforms that became India’s Patents Act of 1970, and for pricing generic AIDS medication affordably for developing countries in the early 2000s.

Is Cipla still run by the Hamied family?

Yes — as of recent record, Yusuf Hamied and his brother Mustafa Hamied remain associated with the company’s ownership and leadership lineage.